Several reports found that antibodies against human TIM-3 enhance T cells responses alone or in combination with PD-1 blockers and thus provide a rationale to explore strategies to enhance anti-cancer immunity by targeting TIM-3 (49, 50, 113, 134, 135). Here, HAVCR2 is linked to cancer.